IRVING, Texas--(BUSINESS WIRE)--MPM Medical, Inc., today announced that a peer-reviewed clinical research study of its proprietary product Regenecare® showed effective reduction in severe burning, itching, and rashes, adverse side effects suffered by patients treated with frequently used anti-cancer drugs known as EGFR (Epidermal Growth Factor Receptor) inhibitors. The study was presented at the 33rd Annual Oncology Nursing Society Congress held in Philadelphia, PA this past weekend and attended by approximately 5,000 oncology nurses.
